PT2501704E - Compostos de espiropiperidina como antagonistas do receptor orl-1 - Google Patents

Compostos de espiropiperidina como antagonistas do receptor orl-1

Info

Publication number
PT2501704E
PT2501704E PT107824864T PT10782486T PT2501704E PT 2501704 E PT2501704 E PT 2501704E PT 107824864 T PT107824864 T PT 107824864T PT 10782486 T PT10782486 T PT 10782486T PT 2501704 E PT2501704 E PT 2501704E
Authority
PT
Portugal
Prior art keywords
receptor
antagagonisten
oral
treatment
compounds
Prior art date
Application number
PT107824864T
Other languages
English (en)
Portuguese (pt)
Inventor
Nuria Diaz Buezo
Maria Angeles Martinez-Grau
Alma Maria Jimenez-Aguado
Celia Lafuente Blanco
Miguel Angel Toledo Escribano
Ana Belen Benito Collado
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2501704E publication Critical patent/PT2501704E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT107824864T 2009-11-16 2010-11-12 Compostos de espiropiperidina como antagonistas do receptor orl-1 PT2501704E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
PT2501704E true PT2501704E (pt) 2013-12-05

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107824864T PT2501704E (pt) 2009-11-16 2010-11-12 Compostos de espiropiperidina como antagonistas do receptor orl-1

Country Status (18)

Country Link
US (1) US20120214784A1 (enExample)
EP (1) EP2501704B1 (enExample)
JP (1) JP5723381B2 (enExample)
KR (1) KR101368130B1 (enExample)
CN (1) CN102666550B (enExample)
AU (1) AU2010319400B2 (enExample)
BR (1) BR112012011710A2 (enExample)
CA (1) CA2781041C (enExample)
DK (1) DK2501704T3 (enExample)
EA (1) EA020391B1 (enExample)
ES (1) ES2436241T3 (enExample)
HR (1) HRP20130969T1 (enExample)
MX (1) MX2012005690A (enExample)
PL (1) PL2501704T3 (enExample)
PT (1) PT2501704E (enExample)
RS (1) RS53017B (enExample)
SI (1) SI2501704T1 (enExample)
WO (1) WO2011060217A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
AU2017309725A1 (en) 2016-08-10 2019-02-21 Bayer Cropscience Aktiengesellschaft Substituted 2-heterocyclyl imidazolyl-carboxamides as pest control agents
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
US10603320B2 (en) * 2017-03-02 2020-03-31 Eli Lilly And Company Compounds useful for inhibiting ROR-gamma-t
HUE054483T2 (hu) 2017-03-02 2021-09-28 Lilly Co Eli ROR-gamma-T gátlására alkalmas vegyületek
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
IL283592B2 (en) 2018-12-17 2025-08-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
EP4165036A1 (en) 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
UY39395A (es) 2020-08-26 2022-03-31 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
CA3251050A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1732928A2 (en) * 2004-03-29 2006-12-20 Pfizer, Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2008542375A (ja) * 2005-06-02 2008-11-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Orl−1受容体モジュレーターとして有用な新規3−スピロ環式インドリル誘導体

Also Published As

Publication number Publication date
CA2781041C (en) 2015-01-06
US20120214784A1 (en) 2012-08-23
WO2011060217A1 (en) 2011-05-19
MX2012005690A (es) 2012-06-13
CA2781041A1 (en) 2011-05-19
EP2501704B1 (en) 2013-09-18
BR112012011710A2 (pt) 2016-03-01
ES2436241T3 (es) 2013-12-27
RS53017B (sr) 2014-04-30
AU2010319400B2 (en) 2013-12-19
CN102666550A (zh) 2012-09-12
AU2010319400A1 (en) 2012-06-07
EP2501704A1 (en) 2012-09-26
HRP20130969T1 (hr) 2013-11-22
JP5723381B2 (ja) 2015-05-27
CN102666550B (zh) 2015-07-15
EA020391B1 (ru) 2014-10-30
SI2501704T1 (sl) 2013-11-29
JP2013510870A (ja) 2013-03-28
PL2501704T3 (pl) 2014-02-28
DK2501704T3 (da) 2013-10-14
KR101368130B1 (ko) 2014-02-27
EA201290355A1 (ru) 2012-10-30
KR20120082927A (ko) 2012-07-24

Similar Documents

Publication Publication Date Title
PH12012500969A1 (en) Spiropiperidine compounds as orl-1 receptor antagonists
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
PH12015501289B1 (en) Novel benzimidazole derivatives as ep4 antagonists
MX352881B (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
PH12012500572A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
IN2012DN02735A (enExample)
IN2012DN00754A (enExample)
MX2010009955A (es) Derivados de ciclohexano espirociclicos sustituidos.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MY172809A (en) Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
TN2012000207A1 (en) Spiropiperidine compounds as orl-1 receptor antagonists
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
WO2009108635A3 (en) Novel compositions for treatment of diseases related to activated lymphocytes
CY1114664T1 (el) Ενωσεις σπιροπιπεριδινης ως ανταγωνιστες υποδοχεα orl-1
CL2012001262A1 (es) Compuestos derivados de espiropiperidina; composicion farmaceutica; y uso como antagonistas del receptor orl-1 en el tratamiento de la depresion, migraña, obesidad.
TN2011000063A1 (en) Quinuclidine carbonate derivatives and medicinal composition thereof
UA96037C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия
PH12013501453A1 (en) Nicotinic receptor non-competitive antagonists